Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS -100.00%*·Rev n/aQ1 23EPS +56.25%·Rev n/aQ4 22EPS +100.00%*·Rev n/aQ3 22EPS +70.83%·Rev n/a⚠ consensus missing

10x Genomics, Inc. TXG

Cassie Corneau — Investor Relations

Serge Saxonov — Co-founder and CEO

This quarter's results reinforce the strengths that have always differentiated us — Executive

What this quarter's results demonstrate is the momentum we have as we bring the whole-of-company effort to capturing the full Xenium opportunity — Executive

Justin McAnear — Chief Financial Officer

−4.2%1d on move date−3.7% vs SPY3d−7.3%5d−11.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TXG calls or request research access.

More TXG calls Browse calls Request research access